Ginsenoside Rg1 alleviates lipopolysaccharide-induced neuronal damage by inhibiting NLRP1 inflammasomes in HT22 cells.
Alzheimer's disease
ginsenoside Rg1
inflammation
lipopolysaccharide
reactive oxygen species
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
22
10
2020
accepted:
12
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
Lipopolysaccharide (LPS) is a toxic component of cell walls of Gram-negative bacteria that are widely present in gastrointestinal tracts. Increasing evidence showed that LPS plays important roles in the pathogeneses of neurodegenerative disorders, such as Alzheimer's disease (AD). NADPH oxidase s2 (NOX2) is a complex membrane protein that contributes to the production of reactive oxygen species (ROS) in several neurological diseases. The NLRP1 inflammasome can be activated in response to an accumulation of ROS in neurons. However, it is still unknown whether LPS exposure can deteriorate neuronal damage by activating NOX2-NLRP1 inflammasomes. Ginsenoside Rg1 (Rg1) has protective effects on neurons, although whether Rg1 alleviates LPS-induced neuronal damage by inhibiting NOX2-NLRP1 inflammasomes remains unclear. In the present study, the effect of concentration gradients and different times of LPS exposure on neuronal damage was investigated in HT22 cells, and further observed the effect of Rg1 treatment on NOX2-NLPR1 inflammasome activation, ROS production and neuronal damage in LPS-treated HT22 cells. The results demonstrated that LPS exposure significantly induced NOX2-NLRP1 inflammasome activation, excessive production of ROS, and neuronal damage in HT22 cells. It was also shown that Rg1 treatment significantly decreased NOX2-NLRP1 inflammasome activation and ROS production and alleviated neuronal damage in LPS-induced HT22 cells. The present data suggested that Rg1 has protective effects on LPS-induced neuronal damage by inhibiting NOX2-NLRP1 inflammasomes in HT22 cells, and Rg1 may be a potential therapeutic approach for delaying neuronal damage in AD.
Identifiants
pubmed: 34055081
doi: 10.3892/etm.2021.10214
pii: ETM-0-0-10214
pmc: PMC8145787
doi:
Types de publication
Journal Article
Langues
eng
Pagination
782Informations de copyright
Copyright: © Zhang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Biomed Pharmacother. 2019 Jan;109:84-92
pubmed: 30396095
Pharmacol Ther. 2010 May;126(2):119-45
pubmed: 20153367
Integr Cancer Ther. 2020 Jan-Dec;19:1534735419901160
pubmed: 32054357
Neurosci Lett. 2018 Nov 1;686:161-167
pubmed: 30213621
Curr Pharm Biotechnol. 2020;21(8):667-680
pubmed: 31840608
J Neuroinflammation. 2018 Jan 30;15(1):28
pubmed: 29382344
Biomed Pharmacother. 2020 May;125:110020
pubmed: 32106375
Neurochem Res. 2019 May;44(5):1138-1151
pubmed: 30756214
Immunol Lett. 2012 Feb 29;142(1-2):41-7
pubmed: 22207037
Biomed Pharmacother. 2015 Aug;74:101-10
pubmed: 26349970
Sci Immunol. 2020 Mar 20;5(45):
pubmed: 32198221
Mol Med Rep. 2013 Jan;7(1):47-52
pubmed: 23076300
Int J Mol Med. 2019 Feb;43(2):717-726
pubmed: 30535505
Transl Res. 2016 Jan;167(1):35-45
pubmed: 26024799
Eur J Pharmacol. 2020 Nov 5;886:173439
pubmed: 32871175
Neuroscience. 2015 Apr 30;292:81-9
pubmed: 25724866
Acta Pharmacol Sin. 2020 Apr;41(4):523-534
pubmed: 32203085
Oxid Med Cell Longev. 2020 Feb 27;2020:6431459
pubmed: 32184918
Int Immunopharmacol. 2019 Apr;69:60-70
pubmed: 30677569
DNA Cell Biol. 2015 Apr;34(4):274-81
pubmed: 25757059
Free Radic Biol Med. 2017 Jul;108:940-951
pubmed: 28499911
Int J Biol Sci. 2013 Jun 29;9(6):624-36
pubmed: 23847444
Neuroreport. 2019 Sep 4;30(13):893-900
pubmed: 31373969
Antioxidants (Basel). 2019 Apr 29;8(5):
pubmed: 31035637
Analyst. 2016 Jul 21;141(14):4293-8
pubmed: 27181439
Ageing Res Rev. 2014 May;15:6-15
pubmed: 24561250
J Neurochem. 2016 Jan;136 Suppl 1:29-38
pubmed: 26119245
J Diabetes Res. 2019 Feb 17;2019:8151836
pubmed: 30911553
Appl Physiol Nutr Metab. 2017 Aug;42(8):855-860
pubmed: 28388366
Front Aging Neurosci. 2019 Mar 22;11:64
pubmed: 30967771
Curr Neuropharmacol. 2016;14(2):155-64
pubmed: 26639457
Sci Rep. 2016 Dec 14;6:39303
pubmed: 27966632
Pain. 2020 Apr;161(4):758-772
pubmed: 32195784
J Cell Biochem. 2020 Apr;121(4):2994-3004
pubmed: 31709615
Oxid Med Cell Longev. 2017;2017:6057609
pubmed: 28785377
Curr Pharm Biotechnol. 2018;19(8):644-663
pubmed: 30129409
Mol Neurobiol. 2018 Oct;55(10):8103-8123
pubmed: 29508282
Inflammopharmacology. 2016 Oct;24(5):291-293
pubmed: 27645902
Nutrients. 2020 Feb 27;12(3):
pubmed: 32120800
Stem Cells Int. 2019 Dec 4;2019:5010184
pubmed: 31885611
Curr Med Chem. 2012;19(5):770-9
pubmed: 22214447
Endocrinology. 2019 Apr 1;160(4):947-963
pubmed: 30811529
Cell Mol Neurobiol. 2016 May;36(4):541-51
pubmed: 26162968
Int Immunopharmacol. 2020 Feb 27;82:106339
pubmed: 32114413
Life Sci. 2009 Feb 27;84(9-10):267-71
pubmed: 19135458
J Neuroinflammation. 2015 Jan 28;12:18
pubmed: 25626361
J Ocul Pharmacol Ther. 2019 Dec;35(10):571-577
pubmed: 31825758
Cell Death Dis. 2017 Mar 16;8(3):e2676
pubmed: 28300826
Int Immunopharmacol. 2019 Sep;74:105721
pubmed: 31255881
Front Cell Infect Microbiol. 2017 Jul 11;7:318
pubmed: 28744452
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):311-22
pubmed: 19505385
Neurochem Res. 2017 May;42(5):1299-1307
pubmed: 28078612
Brain. 2013 Sep;136(Pt 9):2677-96
pubmed: 23943781
J Cereb Blood Flow Metab. 2009 Mar;29(3):534-44
pubmed: 19066616
Med Sci Monit. 2019 Apr 13;25:2718-2726
pubmed: 30980521
J Cell Biochem. 2018 Jul;119(7):5528-5537
pubmed: 29377244
Neurology. 2016 Nov 29;87(22):2324-2332
pubmed: 27784770
Curr Alzheimer Res. 2020;17(1):44-51
pubmed: 31797758
Biochem J. 2007 Aug 15;406(1):105-14
pubmed: 17501721
Chem Biol Interact. 2020 Jun 1;324:109062
pubmed: 32198087
Int J Mol Sci. 2016 Nov 18;17(11):
pubmed: 27869744
Neuropharmacology. 2012 Sep;63(3):349-61
pubmed: 22534050